ArticleInternational journal of molecular sciences2020

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.

Nora Sahnane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.